Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Sargramostim by Partner Therapeutics for Non-Small Cell Lung Cancer: Likelihood of Approval
Sargramostim is under clinical development by Partner Therapeutics and currently in Phase II for Non-Small Cell Lung Cancer. According to...
Sargramostim by Partner Therapeutics for Metastatic Melanoma: Likelihood of Approval
Sargramostim is under clinical development by Partner Therapeutics and currently in Phase III for Metastatic Melanoma. According to GlobalData, Phase...
Sargramostim by Partner Therapeutics for Coronavirus Disease 2019 (COVID-19): Likelihood of Approval
Sargramostim is under clinical development by Partner Therapeutics and currently in Phase II for Coronavirus Disease 2019 (COVID-19). According to...
Sargramostim by Partner Therapeutics for Hematological Tumor: Likelihood of Approval
Sargramostim is under clinical development by Partner Therapeutics and currently in Phase II for Hematological Tumor. According to GlobalData, Phase...